secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annovis Bio, Inc. (ANVS)
CIK:        0001477845
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0001104659-25-076851
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annovis Bio Q2 net loss $0.32/sh; cash $17.1M; Phase 3 AD trial advances with 38 patients randomized
--------------------------------------------------------------------------------

- Cash and cash equivalents $17.1M as of June 30, 2025, up from $10.6M at Dec 31, 2024.
- Net loss per share $0.32 (basic/diluted) for Q2 2025 vs $0.44 in Q2 2024.
- Phase 3 early AD trial: 38 patients randomized, nearly 200 in screening, 76 U.S. sites (46 enrolling).
- R&D expenses $5.2M, G&A $1.1M, both down YoY.
- Transferred all patent families to crystal buntanetap, achieving comprehensive global IP coverage.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1477845/000110465925076851/0001104659-25-076851-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1477845/000110465925076851/tm2523281d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-076851

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer